PortfoliosStock ScreensStocksStockXcel

HOOKIPA Pharma Inc

HOOK | US

1.15

USD

0.04

4.07%

HOOK | US

About HOOKIPA Pharma Inc

Sector

Healthcare

Industry

Biotechnology

Earnings date

30/06/2024

As of date

16/04/2026

Close

1.15

Open

1.10

High

1.15

Low

1.10

HOOKIPA Pharma Inc. a clinical stage biopharmaceutical company develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101 which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic colorectal and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment cure diagnosis or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York New York.

View Less

HOOK | US

Risk
41.7
Sharpe
0.68
Luna's Score
51/100
Recommendation
Hold

Luna says (HOOK | US)

What's Working

Positive Momentum

Low Debt to Equity (< 0.25)

Low Debt to Asset (< 0.2)

Value Stock (Price to Book < 3)

What's not Working

High Short-term Volatility

Microcap (<300M USD)

High Market Beta (> 0.8)

Weak Operating Margin (< 10%)

Declining Revenue (< 0%)

Volatility Signals

Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.

Risk Meter

10 days

49.1%

1 month

41.7%

3 months

38.1%

6 months

32.9%

Returns

Fundamental Ratios

PE

-

Fwd. PE

-

Price to book

0.47

Debt to equity

0.06

Debt to assets

0.04

Ent. to EBITDA

0.46

Ent. to rev.

1.91

PEG

-

Other Fundamentals

EBITDA

-47.71M

MarketCap

11.38M

MarketCap(USD)

11.38M

Div. yield

-

Op. margin

-1.74K

Erngs. growth

-

Rev. growth

-51.80

Ret. on equity

-48.99

Short ratio

1.38

Short perc.

0.45

Market Sentiment (SMA and Price signals)

Short-term: Bullish (SMA10D > SMA1M)

Intermediate-term: Bullish (SMA1M > SMA3M)

Long-term: Bearish (SMA6M < SMA12M)

SMAs: Stock Price Trends

Range10D

0.11

Range1M

0.14

Range3M

0.26

Volumes: Market Activity

Rel. volume

0.43

Price X volume

4.72K

Peers

Name
Ticker
Industry
Close
Marketcap
Day Return
PE Ratio
Debt to Equity
 
 
 
 
 
 
 
 
CytoMed Therapeutics Limited Ordinary SharesGDTCBiotechnology1.0211.77M2.02%n/a3.98%
Anebulo Pharmaceuticals Inc. Common StockANEBBiotechnology0.4511.67M-10.00%n/a0.00%
GeoVax Labs IncGOVXBiotechnology1.2310.49M-3.91%n/a-6.03%
Adial Pharmaceuticals IncADILBiotechnology1.6210.38M0.00%n/a0.00%
InMed Pharmaceuticals IncINMBiotechnology0.79.34M-1.74%n/a7.00%
VYNE Therapeutics IncVYNEBiotechnology0.61769.11M-0.37%1.290.19%
Cyclerion Therapeutics IncCYCNBiotechnology2.987.50M-1.65%n/a0.00%
Zivo Bioscience IncZIVOBiotechnology2.157.44M-2.27%n/a-25.20%
KPRXKPRXBiotechnology2.497.40M-1.97%0.210.25%
XORTX Therapeutics Inc. Common StockXRTXBiotechnology2.447.35M12.96%n/a3.09%
  • 1

Diversifiers

Name
Ticker
Industry
Close
Marketcap
Day Return
PE Ratio
Debt to Equity
 
 
 
 
 
 
 
 
REE Automotive Ltd. Class A Ordinary SharesREERecreational Vehicles0.61211.83M-2.84%n/a58.43%
Antelope Enterprise Holdings LimitedAEHLBuilding Products & Equipment0.7410.81M6.52%0.0316.03%
EZGO Technologies Ltd. Ordinary SharesEZGORecreational Vehicles1.3353.41M-2.06%n/a17.32%
Twin Vee PowerCats Co. Common StockVEEERecreational Vehicles0.21672.06M-6.19%n/a19.98%
Vision Marine Technologies IncVMARRecreational Vehicles1.44793.44K-17.24%n/a0.00%
Micromobility.com Inc.MCOMRecreational Vehicles0.005461.07K0.00%n/a-37.05%
  • 1

Industry Comparison

ParameterCompanyIndustryIndicator
Enterprise to EBITDA0.46-Par
Ent. to Revenue1.91-Cheaper
PE Ratio-41.03-
Price to Book0.4715.55Cheaper
Dividend Yield---
Std. Deviation (3M)38.08-Lower Risk
Debt to Equity0.06-1.23Expensive
Debt to Assets0.040.25Cheaper
Market Cap11.38M-Emerging
  • 1

Unlock Your Investing Potential

Register with Xstocks

Join over 2,000+ Investors

Register now and embark on your journey to informed and successful investing.

Explore Industry Correlations

Explore Industry Correlations

Uncover Trading and Hedging Opportunities

Gain valuable insights into potential trading opportunities and discover strategic hedging possibilities

Discover Top-Performing Industries

Discover Top performing Industries

Explore Stocks for Short and Long-Term Gains

Uncover opportunities at both short-term and long-term horizons, allowing you to make informed investment decisions.

Follow us @XStocks007